BCR/integrin interaction in CLL: a physiological remnant with clinical relevance.
Erika TissinoRiccardo BombenValter GatteiAntonella ZucchettoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
CD49d, the alpha chain of the VLA-4 integrin, has a negative prognostic impact in CLL treated with the BTK-inhibitors ibrutinib and acalabrutinib. Despite BTK inhibition, VLA-4 remains inside-out activated via BCR, an activation dampened by PI3K-inhibitors. Evaluation of CD49d expression in patients starting BTK-inhibitor therapy may improve their prognostic stratification.
Keyphrases
- tyrosine kinase
- chronic lymphocytic leukemia
- end stage renal disease
- acute lymphoblastic leukemia
- newly diagnosed
- ejection fraction
- chronic kidney disease
- poor prognosis
- prognostic factors
- chronic myeloid leukemia
- peritoneal dialysis
- stem cells
- patient reported outcomes
- nk cells
- long non coding rna
- mesenchymal stem cells
- binding protein
- smoking cessation